These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16220559)

  • 1. Matrix metalloproteinases in carcinoma of unknown primary.
    Karavasilis V; Malamou-Mitsi V; Briasoulis E; Tsanou E; Kitsou E; Kalofonos H; Fountzilas G; Fotsis T; Pavlidis N
    Cancer; 2005 Nov; 104(10):2282-7. PubMed ID: 16220559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
    Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
    Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
    Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
    Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
    Massi D; Franchi A; Ketabchi S; Paglierani M; Pimpinelli N; Santucci M
    Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
    Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
    Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
    Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
    Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.
    Thomas P; Khokha R; Shepherd FA; Feld R; Tsao MS
    J Pathol; 2000 Feb; 190(2):150-6. PubMed ID: 10657012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
    Giannopoulos G; Pavlakis K; Parasi A; Kavatzas N; Tiniakos D; Karakosta A; Tzanakis N; Peros G
    Anticancer Res; 2008; 28(3B):1875-81. PubMed ID: 18630474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease.
    Rosemar A; Ivarsson ML; Börjesson L; Holmdahl L
    Scand J Gastroenterol; 2007 Feb; 42(2):215-20. PubMed ID: 17327941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
    Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
    J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer.
    Luukkaa H; Klemi P; Hirsimäki P; Vahlberg T; Kivisaari A; Kähäri VM; Grénman R
    Acta Otolaryngol; 2008 Apr; 128(4):482-90. PubMed ID: 18368586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
    Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
    J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
    Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
    Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
    Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
    Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.